Skip to main content

Advertisement

Figure 6 | Reproductive Biology and Endocrinology

Figure 6

From: Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway

Figure 6

No changes were detected after transfection with EGFR siRNA, either with or without JMR-132 treatment. A. EGFR was knocked down after transfection with EGFR siRNA for various periods of time. After transfection with 100 nM EGFR siRNA for 48 hours, we reseeded the cells for the MTT assay. Pretreatment: after cell reseeding; 48 and 96 hours: treatment with 100 nM JMR-132 per day for 2 and 4 days after cell reseeding. The EGFR expression was still lower when compared to the cells transfected with 100 nM control siRNA. B. No changes were found by the MTT assay after transfection with EGFR siRNA, with or without JMR-132 treatment. The cells (SKOV3 and CaOV3: 4000/well) were reseeded in a 96-well plate after transfection with control siRNA or EGFR siRNA for 2 days. After 2 and 4 days of treatment with 100 nM JMR-132, the MTT assay was performed. Letters (a, b, c) indicate significant differences (P < 0.05) between pairs. C. No changes were detected in cleaved caspase3 expression after transfection with EGFR siRNA, either with or without JMR-132 treatment in SKOV3 cells. After transfection with 100 nM EGFR siRNA for 48 hours, the SKOV3 cells were treated with 100 nM JMR-132 per day for 2 days. β-actin was used as an internal control.

Back to article page